CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding CNS Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 12 | 12 | 0 |
| Shares | 104.8K | 116.7K | +11.9K (+11.4%) |
| Value | $234.4K | $131.7K | −$102.8K (−43.8%) |
New holders (2)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 21,428 | $24.0K | 0.00% |
| Morgan Stanley | 67 | $76 | 0.00% |
Sold out (2)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Acadian Asset Management LLC | 22,292 | $49.0K |
| Advisor Group Holdings, Inc. | 42 | $94 |